相似文献
1
Colorectal cancer prognosis: is it all mutation, mutation, mutation?
Gut. 2005 Sep;54(9):1209-11. doi: 10.1136/gut.2005.070946.
2
3
Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer.
Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9433-8. doi: 10.1073/pnas.122612899. Epub 2002 Jul 1.
4
Detection of APC and k-ras mutations in the serum of patients with colorectal cancer.
Cancer Detect Prev. 2001;25(1):55-61.
5
Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
J Gastrointestin Liver Dis. 2007 Mar;16(1):11-7.
6
The balanced induction of K-ras codon 12 and 13 mutations in mucosa differs from their ratio in neoplastic tissues.
Int J Oncol. 2006 Oct;29(4):957-64.
7
No difference in the occurrence of mismatch repair defects and APC and CTNNB1 genes mutation in a multi-racial colorectal carcinoma patient cohort.
Pathology. 2007 Apr;39(2):228-34. doi: 10.1080/00313020701230757.
8
p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
Cancer Lett. 2004 Jul 8;210(1):101-9. doi: 10.1016/j.canlet.2004.01.006.
9
Aberrant crypt foci as precursors of the dysplasia-carcinoma sequence in patients with ulcerative colitis.
Clin Cancer Res. 2008 Jan 1;14(1):48-54. doi: 10.1158/1078-0432.CCR-07-1835.
10
The prognostic value of c-Kit, K-ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer.
Cancer. 2010 Nov 1;116(21):4954-64. doi: 10.1002/cncr.25417.
引用本文的文献
1
Survival outcome prediction of esophageal squamous cell carcinoma patients based on radiomics and mutation signature.
Cancer Imaging. 2025 Jan 31;25(1):9. doi: 10.1186/s40644-024-00821-5.
2
Impact of socioeconomic status on cancer care in Southeast Texas: a retrospective population-based cohort study.
Proc (Bayl Univ Med Cent). 2024 Jul 22;37(5):782-793. doi: 10.1080/08998280.2024.2375489. eCollection 2024.
3
Distinct roles and differential expression levels of Wnt5a mRNA isoforms in colorectal cancer cells.
PLoS One. 2017 Aug 31;12(8):e0181034. doi: 10.1371/journal.pone.0181034. eCollection 2017.
4
Expression Pattern and Clinicopathological Relevance of the Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase Protein in Colorectal Cancer.
Dis Markers. 2016;2016:8169724. doi: 10.1155/2016/8169724. Epub 2016 Aug 8.
5
High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.
BMC Cancer. 2006 Dec 21;6:295. doi: 10.1186/1471-2407-6-295.
6
p53 protein accumulation as a prognostic marker in sporadic colorectal cancer.
Int J Colorectal Dis. 2007 May;22(5):499-506. doi: 10.1007/s00384-006-0194-6. Epub 2006 Oct 5.
本文引用的文献
1
The human cancer genome project--one more misstep in the war on cancer.
Nat Biotechnol. 2005 May;23(5):535-7. doi: 10.1038/nbt0505-535.
2
The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma.
Gut. 2005 Sep;54(9):1283-6. doi: 10.1136/gut.2005.066514. Epub 2005 Apr 20.
3
Wnt signalling in stem cells and cancer.
Nature. 2005 Apr 14;434(7035):843-50. doi: 10.1038/nature03319.
4
Genomic determinants of prognosis in colorectal cancer.
Cancer Lett. 2005 Apr 18;221(1):1-9. doi: 10.1016/j.canlet.2004.08.023.
5
Genetic predisposition to colorectal cancer.
Nat Rev Cancer. 2004 Oct;4(10):769-80. doi: 10.1038/nrc1453.
6
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
N Engl J Med. 2004 Jul 22;351(4):337-45. doi: 10.1056/NEJMoa033025.
7
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691.
8
Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex.
Cancer Cell. 2004 Jan;5(1):91-102. doi: 10.1016/s1535-6108(03)00334-9.
9
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays.
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14229-34. doi: 10.1073/pnas.2331323100. Epub 2003 Nov 17.
10
Genetic pathways and genome-wide determinants of clinical outcome in colorectal cancer.
Cancer Res. 2003 Nov 1;63(21):7206-14.
Zotero 插件